Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Darbepoetin

Phase 3Small molecule

Darbepoetin is one of 87 small molecule programs targeting Cirrhosis. It is currently in Phase 3.

2

Indications

9

Total Trials

3

Active Trials

86

Competitors

Pipeline

Status by Indication[3][1]

Indication

CirrhosisActive, not recruiting

Liver TransplantRecruiting

CirrhosisPreclinical

Active, not recruiting

Liver TransplantPhase 3

Recruiting

Competition

Competitive Landscape

96 competitors in Liver Transplant

#DrugCompanyPhaseTrials

Giapreza

LLa Jolla Pharmaceutical Company

Prothrombin Complex Concentrate

Darbepoetin

Tacrolimus Pill

EEdward Geissler

Lenvima

Octreotide

Johnson & Johnson

Prostigmin

Beyfortus

Myfortic

Cyklokapron

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Liver Transplant

NCT07169643

Q4 2031

N/ANot yet recruiting

Cirrhosis

NCT07131280

Clinical

Trials by Indication[1]

Myelodysplastic Syndromes2 trials

Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)

Unknown status·GGroupe Francophone des Myelodysplasies·Phase 2·NCT00443339·99 enrolled

Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)

Unknown status·SSt. Bartholomew's Hospital·Phase 2/3·NCT00234143·360 enrolled

Cirrhosis2 trials

Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.

Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT07002827·60 enrolled

National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis

Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT07131280·110 enrolled

Dialysis1 trial

Long-term Pre-dialysis Extension in Europe and Asia Pacific

Completed· Bayer logo

Bayer·Phase 2·NCT02055482·166 enrolled

Nephropathy1 trial

Effect of Darbepoetin in Contrast-induced Nephropathy

Terminated·SSeoul National University Bundang Hospital·Phase 2/3·NCT01197235·80 enrolled

Hypertension1 trial

Mechanisms of EPO-induced Hypertension

Terminated·VVA Office of Research and Development·Phase 2·NCT03810911·27 enrolled

2 more indications

Liver Transplant1 trial

Darbepoetin in Patients Candidates for Liver Transplant. (EPO-LT Trial)

Recruiting·FFundacion Clinic per a la Recerca Biomédica·Phase 3·NCT07169643·140 enrolled

Neurocognitive1 trial

Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants

Completed·NNICHD Neonatal Research Network·Phase 3·NCT03169881·650 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Darbepoetin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Darbepoetin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Darbepoetin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bayer

Related News